Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.51 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | IL1B | P01584 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128674 | 0.73 | CRBN (0.56) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL22789034 | 0.73 | CRBN (0.44) | CRBNDDB1IKZF3GPBAR1L3MBTL1 | |
| SCHEMBL283716 | 0.70 | CRBN (0.56) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL3655103 | 0.70 | CRBN (0.57) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL18900415 | 0.70 | CRBN (0.56) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL633124 | 0.70 | CRBN (0.58) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671748 | 0.70 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL21671745 | 0.70 | CRBN (0.63) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL16770151 | 0.69 | CRBN (0.57) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20812031 | 0.69 | SMN1; SMN2 (0.54) | CRBNDDB1IKZF3ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885DDB1 433/4885IKZF3 3470/4885 |
| US-11384063-B2 | Modulators of estrogen receptor proteolysis and associated methods of use | ADRM1, MDM2, ESR2 | CRBN 5/4885DDB1 424/4885IKZF3 1222/4885 |
| US-20200199107-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ADRM1, MDM2, ESR2 | CRBN 5/4885DDB1 424/4885IKZF3 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.